

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8015081


SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AIMESTHER BETANCOURT	11/19/2015
CHARLES UZARAMA	11/19/2015
ROCH THIBERT	11/19/2015
RECEIVING PARTY DATA	
Name:	COREALIS PHARMA INC.
Street Address:	200 ARMAND FRAPPIER BLVD.
City:	LAVAL, QUEBEC
State/Country:	CANADA
Postal Code:	H7V 4A6
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15370980
CORRESPONDENCE DATA	
Fax Number:	(608)662-1276
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6086621277
Email:	mrfugate@casimirjones.com
Correspondent Name:	ANNE M. REYNOLDS
Address Line 1:	2275 DEMING WAY
Address Line 2:	SUITE 310
Address Line 4:	MIDDLETON, WISCONSIN 53562
ATTORNEY DOCKET NUMBER:	UM-40284.304
NAME OF SUBMITTER:	ANNE M. REYNOLDS
SIGNATURE:	/Anne M. Reynolds/
DATE SIGNED:	06/20/2023
Total Attachments: 4	
source=2_Assignment_Betancourt-Uzarama-Tibert_COREALIS PHARMA INC#page1.tif	
source=2_Assignment_Betancourt-Uzarama-Tibert_COREALIS PHARMA INC#page2.tif	
source=2_Assignment_Betancourt-Uzarama-Tibert_COREALIS PHARMA INC#page3.tif	

ASSIGNMENT

WHEREAS, we,

Name	Mailing Address	
Aimesther Betancourt	8282 Avenue Nicolas-Leblanc, Montréal, QC, CA H1E 3W5	;
Charles Uzarama	180 Avenue de l'Élysée, Laval, QC, CA H7W 3Y6	; and
Roch Thibert	948 Chemin Moncrieff, Ville Mont-Royal, QC, CA H3R 3A4	;

(hereinafter referred to as ASSIGNORS), having post office addresses as listed above, respectively, are the joint inventors of an invention entitled
“SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO,” as described and claimed in the specification for which an application for United States letters patent was filed on September 25, 2015, and assigned Application No. 14/866,212; and for which an application was filed on September 25, 2015 with the U.S. Receiving Office of the PCT and assigned Application No. PCT/US2015/052338; and for which a U.S. Provisional Application was filed on September 26, 2014, and December 1, 2014 and assigned Application Nos. 62/055,964, and 62/086,153, respectively;

WHEREAS, Corealis Pharma Inc.  (hereinafter referred to as ASSIGNEE), a corporation having a place of business at 200, Armand Frappier Blvd., Laval, Quebec, Canada H7V 4A6, is desirous of acquiring the entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNORS hereby sell, assign and transfer unto said ASSIGNEE, the entire right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions including any extensions or adjustments in term thereof and in any and all foreign countries, and in any and all divisions, reissues and

1089


continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, and including the right to sue and collect damages for past and present infringement of said letters patent; said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit and of their successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNORS had this assignment, transfer and sale not been made. ASSIGNORS hereby authorize and request the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNORS agree to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention, for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

This assignment is made effective as of September 24, 2015.

Date 2015/09/19 _____ (Assignor)
Aimesther Betancourt

I certify that I know or have satisfactory evidence that Aimesther Betancourt signed this instrument of his/her own free will, as a voluntary act for the uses and purposes mentioned in the instrument.

Date 2015/09/19 _____ Signed at Laval _____
Linda Gagnon _____
(Name of Witness) (Signature of Witness)

Date 2015 NO 19

(Assignor)
Charles Uzarama

I certify that I know or have satisfactory evidence that Charles Uzarama signed this instrument of his/her own free will, as a voluntary act for the uses and purposes mentioned in the instrument.

Date 2015 NO 19Signed at LavalLinda Gagnon
(Name of Witness)Linda Gagnon
(Signature of Witness)Date 2015-NO-19


(Assignor)
Roch Thibert

I certify that I know or have satisfactory evidence that Roch Thibert signed this instrument of his/her own free will, as a voluntary act for the uses and purposes mentioned in the instrument.

Date 2015-NO-19Signed at LavalLinda Gagnon
(Name of Witness)Linda Gagnon
(Signature of Witness)

COREALIS PHARMA Inc. 

2015/10/19
Date

 (Assignee)
(Signatory Signature)

YVES ROY, President
(Assignee Signatory Name, Title)

4495937_1.DOC